葉酸受容体α陽性進行卵巣がんおよびその他の固形腫瘍を有する成人被験者を対象としたTAK-853の試験

基本情報

NCT ID

NCT06390995

ステータス

実施中（募集終了）

試験のフェーズ

第1/第2相

試験タイプ

介入

目標被験者数

28

治験依頼者名

Takeda

概要

The main aim of this study are to check for side effects from TAK-853, check how much TAK-853 participants can receive without getting side effects from it, check how well TAK-853 controls symptoms, and to check how much TAK-853 stays in their blood over time. The study will be conducted in two phases including Phase 1 Part and Phase 2 Part. In Phase 1 Part, the participants will stay in the hospital for 3 days at least after their 1st injection for some tests and to check for any side effects from their treatment. In Phase 2 Part, participants will visit their study hospital for multiple times. In both phases, the participants will receive TAK-853 on the first days of each 3-week cycle. The participant will be in the study for about 9 months in Phase 1 Part and for about 24 months in Phase 2 Part. The study doctors will check for side effects from the study treatments.

対象疾患

介入

依頼者（Sponsor）

実施施設 (24)